A Case of Denosumab-Associated Hyperparathyroidism: A Differential Diagnostic Challenge
European journal of geriatrics and gerontology(2022)
摘要
Denosumab is a relatively new medicine that has become the second option in the treatment of biphosphonate-resistant or intolerant osteoporosis. Subcutaneous injection with 6-month intervals, approval of its usage in stage 3-4 CKD and not having gastrointestinal side effects are advantages of denosumab. However, it has some disadvantages like requiring monitoring serum levels of calcium and vitamin D before each injection.
更多查看译文
关键词
Bone health in older people,clinical geriatrics,denosumab,drugs and aging,geriatrics,osteoporosis
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要